Specipig closed 2021 achieving 150 preclinical research projects and reinforcing its position as the reference preclinical Contract Research Organisation (CRO) for the global pharmaceutical, biotechnology and medical technology industry.
The projects include efficacy, safety and tolerance studies for new biomedical components, stem cell implants, dental implants, kidney transplants and the validation of latest-generation surgical robots like Bitrack, among others.
Jaume Amat, CEO of Specipig, notes that the company ended the year positively for the third time in a row since it started in 2013, increasing 50% from last year: “We believe these results are very positive because they show a consolidation of Specipig’s growth in line with our goals and they mean we can continue investing in cutting-edge facilities and talent.” 99% of the company’s revenue is international, with clients in more than 10 countries.
In 2022, Specipig will continue boosting its local and international presence. “Despite being a small CRO, our experience and specialisation are unique and highly valued in the industry, as are our agility, flexibility and open doors for our customers,” explains Specipig Business Development Manager Assela Bosch.
Specipig has facilities near Barcelona airport, a strategic location to collaborate with international experts, and a team of 20 qualified professionals (20% hold a PhD and 55% graduate degrees).
In terms of animal-welfare and quality accreditations, the company has Good Laboratory Practices (GLP) certification and meets the guidelines issued by the European Medicines Agency (EMA), the US Food and Drug Agency (FDA), ISO 10993 and other relevant healthcare authorities. In the coming months, the company expects to receive ISO 13485 certification for medical devices and the accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
Photo: Specipig CEO Jaume Amat and Specipig Business Development Manager Assela Bosch.